On March 17, 2021 Amplia Therapeutics Ltd (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment for cancer and fibrosis, reported that it has successfully completed the dosing of subjects in the Single Ascending Dose (SAD) component of the Phase 1 clinical trial of its proprietary focal adhesion kinase (FAK) inhibitor AMP945 (Press release, Amplia Therapeutics, MAR 17, 2021, View Source;[email protected] [SID1234576815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Single Ascending Dose study involved four cohorts of healthy volunteers. The last cohort of volunteers received the highest single dose of AMP945 administered to date and achieved drug exposures corresponding to the maximum allowable level specified in the trial design. As noted for prior cohorts, the highest single dose AMP945 was found to be well tolerated and no safety concerns were identified.

Last month, Amplia announced that it had started dosing subjects for the Multiple Ascending Dose (MAD) component of its Phase 1 trial. The Company remains on track to complete dosing and report top-line data from this trial in the June quarter. Dr John Lambert, CEO of Amplia commented: "We are very encouraged by the data that is coming in from this Phase 1 clinical study. Our focus is now on completing the trial in a timely manner, fully analysing the data and preparing for future clinical studies in patients with cancer and fibrosis."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.